Values obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy. This procedure does not provide serial monitoring; it is intended for one-time use only. If serial monitoring is required, please use the serial monitoring number 480137 to order.
3 - 10 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
0.3 mL (Note: This volume does not allow for repeat testing.)
Red-top tube or gel-barrier tube
Transfer separated serum to a plastic transport tube as quickly as possible after the clot has formed (within 30 minutes of collection).
Hemolysis; gross icterus; plasma specimen
An aid in the detection and monitoring of neuroendocrine tumors (NETs), particularly those associated with small-cell lung cancer (SCLC)
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Because erythrocytes a contain large amount of NSE, hemolysis can cause falsely elevated levels.1
The ThermoFisher/BRAHMS KRYPTOR® assay employs Time-Resolved Amplified Cryptate Emission (TRACE) technology based on a non-radioactive energy transfer between a donor (europium cryptate) and an acceptor (XL665) in a sandwich immunofluorescent format using two mouse monoclonal antibodies.
Neuron-specific enolase (NSE) is an enzyme that is found in the cytoplasm of neurons and neuroendocrine cells.2,3 The production of NSE occurs late in neural differentiation, thus making NSE an index of neural maturation.2 Increased serum levels of NSE may occur in patients with of neuroendocrine tumors (NETs).2,4-13 A number of NETs are considered to be “nonfunctioning” in that they do not produce elevated serum concentrations of substances that cause endocrine symptoms. NSE is similar to chromogranin A (CgA) in that it can serve as a general neuroendocrine tumor marker that can be of clinical value in in the assessment of non-functioning tumors.4,14 NSE can be particularly useful in the assessment of patients with high-grade, poorly differentiated tumors.4,14
Serum NSE levels are often elevated in patients with small-cell lung cancer (SCLC) and NSE levels are applied as a biomarker for disease staging and monitoring.3,11,13-27 NSE levels have been shown to correlate with tumor burden, number of metastatic sites and response to treatment in SCLC.6,28,29 A meta-analysis of 11 studies determined that SCLC patients with higher levels of NSE had a poorer prognosis than those with lower levels of NSE.30
Increased levels of NSE have been also reported in non-small cell lung cancer (NSCLC).2,31,32 Differentiation between SCLC and NSCLC can have prognostic and therapeutic value, due to the dissimilar behavior of these malignancies.2,33 In a comparative analysis of the performance of several NSE assays, Stern and coworkers found that the Brahms Kryptor assay had a 22% sensitivityfor distinguishing cancer patients (SCLC and NSCLS) from benign lung disease with a specificity of 95% using a cut-off concentration of 20 ug/L.34 In the same study, the Brahms assay had a 55% sensitivity for distinguishing SCLC form NSCLS at 95% specificity,34 employing an NSE cut-off of 21ug/L. This was the highest sensitivity of the seven NSE methods evaluated.
Raised serum levels of NSE have been found in patients with neuroblastoma, especially in widespread and metastatic disease, with high serum levels correlated with significantly worse outcome in terms of disease-free survival.35-37 Increased serum NSE levels have also been observed in patients with diverse conditions including: melanoma, seminoma, renal cell carcinoma, Merkel cell tumor, carcinoid tumors, dysgerminomas and immature teratomas, malignant pheochromocytoma, Guillain-Barrésyndrome and Creutzfeldt-Jakob disease.2
Measurement of serum NSE has been applied to the assessment of neuronal injury37 and the estimation of brain damage in conditions including: ischemic stroke,38 intracerebral hemorrhage,39,40 seizure,41 after cardiopulmonary resuscitation for cardiac arrest42 and in traumatic brain injury.43
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|140624||Neuron-specific Enolase, Serum||57371-7||140690||Neuron-specific Enolase, Serum||ng/mL||57371-7|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf